Calcium channel blockers, angiotensin receptor blockers, and angiotensin-converting enzyme inhibitors: Effectiveness in combination with diuretics or β-blockers for treating hypertension

Vascular Health and Risk Management

Volumn 3, Issue 5, 2007, Pages 579-585

  Bisognano, John D ^a   McLaughlin, Trent ^b   Roberts, Craig S ^c   Tang, Simon S K ^c  

^a UNIVERSITY OF ROCHESTER MEDICAL CENTER   (United States)

^b Wolters Kluwer   (United States)

^c PFIZER INC   (United States)

Author keywords

Amlodipine besylate; Hypertension; Joint National Committee (JNC) 6 and 7; Lisinopril; Valsartan

Indexed keywords

AMLODIPINE BESYLATE; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; DIHYDROPYRIDINE DERIVATIVE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; LISINOPRIL; VALSARTAN;

ADD ON THERAPY; ANTIHYPERTENSIVE ACTIVITY; BLOOD PRESSURE MEASUREMENT; COHORT ANALYSIS; DIABETES MELLITUS; DIASTOLIC BLOOD PRESSURE; DRUG EFFICACY; ELECTRONIC MEDICAL RECORD; GOAL ATTAINMENT; HEALTH CARE ORGANIZATION; HUMAN; HYPERTENSION; MONOTHERAPY; PRIMARY MEDICAL CARE; RETROSPECTIVE STUDY; REVIEW; SYSTOLIC BLOOD PRESSURE; UNITED STATES;

ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; CALCIUM CHANNEL BLOCKERS; DIURETICS; DRUG THERAPY, COMBINATION; HUMANS; HYPERTENSION; RECEPTORS, ANGIOTENSIN;

EID: 36148938672     PISSN: 11766344     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (26)

1. ALLHAT Collaborative Research Group. 2002. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA, 288:2981-97.
2. American Diabetes Association. 2002. Treatment of hypertension in adults with diabetes. Diabetes Care, 25:199-201.
3. Bakris GL. 2001. A practical approach to achieving recommended blood pressure goals in diabetic patients. Arch Intern Med, 161:2661-7.
4. Benson & Hartz AJ. 2000. A comparison of observational studies and randomized, controlled trials. Am J Ophthalmol, 130:688.
5. Bisognano J, McLaughlin T, Roberts CS, et al. 2004. Incremental effectiveness of amlodipine besylate in the treatment of hypertension with single and multiple medication regimens. Am J Hypertens, 17:676-83.
6. Black HR, Elliott WJ, Grandits G, et al. 2003. Principal results of the Controlled ONset Verapamil INvestigation of Cardiovascular Endpoints (CONVINCE) trial. JAMA, 289:2073-82.
7. Burnier M, Schneider MP, Chiolero A, et al. 2001. Electronic compliance monitoring in resistant hypertension: the basis for rational therapeutic decisions. J Hypertens, 19:335-41.
8. Charlson ME, Pompei P, Ales KL, et al. 1987. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis, 40:373-83.
9. Chobanian AV, Bakris GL, Black HR, et al. 2003. Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension, 42:1206-52.
10. Concato J, Shah N, Horwitz RI. 2000. Randomized, controlled trials, observational studies, and the hierarchy of research designs. N Engl J Med, 342:1887-92.
11. D'Agostino RB Jr. 1998. Propensity score methods for bias reduction in the comparison of a treatment to a non-randomized control group. Stat Med, 17:2265-81.
12. Dahlöf B, Devereux RB, Kjeldsen SE, et al. 2002. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet, 359:995-1003.
13. Dahlöf B, Sever PS, Poulter NR, et al. 2005. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled trial. Lancet, 366:895-906.
14. Guidelines Committee. 2003. European Society of Hypertension-European Society of Cardiology guidelines for the management of arterial hypertension. J Hypertens, 21:1011-53.
15. Hajjar I, Kotchen TA. 2003. Trends in prevalence, awareness, treatment, and control of hypertension in the United States, 1988-2000. JAMA, 290:199-206.
16. Hansson L, Zanchetti A, Carruthers SG, et al. 1998. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. HOT Study Group. Lancet, 351:1755-62.
17. Izzo JL Jr, Levy D, Black HR. 2000. Clinical Advisory Statement. Importance of systolic blood pressure in older Americans. Hypertension, 35:1021-4.
18. Joint National Committee on, Detection, Evaluation, and Treatment of High Blood Pressure. 1997. The Sixth Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Arch Intern Med, 157:2413-46.
19. Julius S, Kjeldsen SE, Weber M, et al. 2004. Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial. Lancet, 363:2022-31.
20. Lewis EJ, Hunsicker LG, Clarke WR, et al. 2001. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med, 345:851-60.
21. Materson BJ, Reda DJ, Cushman WC, et al. 1993. Single-drug therapy for hypertension in men: a comparison of six antihypertensive agents with placebo. The Department of Veterans Affairs Cooperative Study Group on Antihypertensive Agents. N Engl J Med, 328:914-21.
22. Monane M, Bohn RL, Gurwitz JH, et al. 1997. The effects of initial drug choice and comorbidity on antihypertensive therapy compliance: results from a population-based study in the elderly. Am J Hypertens, 10:697-704.
23. Petri H, Urquhart J. 1991. Channeling bias in the interpretation of drug effects. Stat Med, 10:577-81.
24. Romano PS, Roos LL, Jollis JG. 1993. Adapting a clinical comorbidity index for use with ICD-9-CM administrative data: differing perspectives. J Clin Epidemiol, 46:1075-97.
25. Staessen JA, Wang JG, Thijs L. 2003. Cardiovascular prevention and blood pressure reduction: a quantitative overview updated until 1 March 2003. J Hypertens, 21:1055-76.
26. Turnbull F, Neal B, Algert C, et al. 2005. Effects of different blood pressure-lowering regimens on major cardiovascular events in individuals with and without diabetes mellitus: results ofprospectively designed overviews of randomized trials. Arch Intern Med, 165:1410-19.